Market research
AOHA.F Rua Life Sciences Plc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 23M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB0033360586
- Market cap
- 23M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.99
About
About Rua Life Sciences Plc
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AOHA.F discussion.
5 years, 5 months ago
Rua Life Sciences Plc is currently in a long term downtrend where the price is trading 10.3% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.2.
Rua Life Sciences Plc's total revenue sank by 0.0% to $152K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-79K since the same quarter in the previous year.
Finally, its free cash flow fell by 585.2% to $-278K since the same quarter in the previous year.
Based on the above factors, Rua Life Sciences Plc gets an overall score of 1/5.